Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 01/06

20060020109 - Therapeutic peptides for demyelinating conditions: The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition....

20060020110 - Synthetic peptides that bind to the hepatitis b virus core and e antigens: The present invention relates generally to the field of virology. More particularly, the invention relates to the discovery that peptides, which bind to the Hepatitis B virus (HBV) core and e antigens, can be used to inhibit HBV infection. Embodiments concern “binding partners”, which include peptides, peptidomimetics, and chemicals that...

20060020111 - Method of aminoacylating trna: It is intended to provide a method of chemically synthesizing an aminoacyl tRNA which is completely different from the existing methods, namely, a highly efficient and practically usable method for synthesizing an aminoacyl tRNA whereby any nonnatural amino acid can be conveniently aminoacylated without a need for genetic engineering techniques...

20060020112 - Methods for identifying modulators of transcriptional activator protein interactions: The present invention relates to methods for identifying interacting regions of transcription factors, and methods for identifying agents which modulate the interactions, useful for affecting gene regulation, for example, cellular transformation. A site within residues 130-154 and within residues 343-358 in Stat3 were found to interact with the transcription factor...

20060020114 - Apo-2dcr: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided....

20060020115 - Nematode neuromuscular junction gaba receptors and methods related thereto: The present invention relates to the field of GABA receptor structure and function. In one aspect, the present invention relates to impairment of the gamma-aminobutyric acid (GABA) receptors in parasitic nematodes, for the purpose of crop protection and/or soil treatment. The invention includes mutated nematode GABA receptor subunits, nematode GABA...

20060020113 - Serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four...

20060020116 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated...

20060020117 - Therapeutic human albumin solutions with low prekallicrein activator (pka) activity and process for obtaining them: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin...

20060020118 - Monoclonal antibodies to type i interferon receptor: Anti-IFNAR1 monoclonal antibodies with neutralizing activities against the anti-viral cytopathic effects of various type I interferons are provided....

20060020119 - Monoclonal antibodies to gastrin hormone: The present invention provides monoclonal antibodies (MAbs) selective for the N-termini and C-termini of the gastrin hormone forms, gastrin-17 (G17), glycine-extended gastrin-17 (G17-Gly), gastrin-34 (G34) and glycine-extended gastrin-34 (G34-Gly); and the hybridomas that produce these MAbs. Also provided are panels of MAbs useful for the detection and quantitation of gastrin-17...

20060020120 - Methods for removing suspended particles from soluble protein solutions: The present invention provides soluble protein solutions, free of suspended particles in high yield. More particularly, the current invention provides a method for removing suspended particles from soluble protein solutions by filtering the soluble protein solution through highly purified diatomaceous earth....

20060014926 - Human papillomavirus polypeptides and immunogenic compositions: The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides...

20060014927 - Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compound (and its conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, is non-phosphorylated, is redox-stable in vivo, is...

20060014928 - Scorpion peptide as hypotensive agent: The present invention provides isoformes from a peptide family belonging to South American scorpion Tityus serrulatus that acts as hypotensive agents by potentiating Bradykinin and, therefore, can be used as anti-hypertensive drugs. A peptide was firstly isolated from Tityus serrulatus venom and showed a strong and long-lasted hypotensive activity when...

20060014929 - Liquid phase peptide synthesis of kl-4 pulmonary surfactant: The invention realtes to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu4)4-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the α-carbon....

20060014930 - Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses: The present invention relates to novel synthetic or natural peptides for use in treating viral or parasitic infections or in the treatment of tumors. The peptides of the present invention are less than 30 amino acids in size, preferably less than 20 amino acids, in particular 15 to 20 amino...

20060014931 - Novel promoter: Disclosing a promoter of the protease MDTS9, which is induced by TGF-β, which is involved in the metabolism of extracellular matrix, and in which the expression of the gene thereof is elevated in renal failure model animals, which promoter is useful as a tool for screening an agent for treating...

20060014932 - Purified and isolated protein zero related (pzr) and therapeutic and screening methods using same: Isolated and purified proteins and nucleic acids including a novel member of the immunoglobulin super-family characterized as having SHP-2 binding activity and cell signaling activity and called protein zero related or PZR, and cDNA encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along...

20060014933 - Using amines or amino acids as mobile phase modifiers in chromatography: This invention relates to the use of amine, amino acid or amino acid ester mobile phase modifiers in normal phase chromatography to improve the resolution and/or productivity of peptide and lipopeptide purification. This chromatographic method can be used for either on analytical or preparative scale purification....

20060014934 - Crystal structure of factor vai and method for identifying blood factor va modulators: The present invention shows the crystal structure of protein C inactivated factor Va (A1-A3-C1-C2) that depicts a novel domain arrangement. The newly disclosed orientation has implications for binding to membranes essential for function. A high-affinity calcium binding site and a copper binding site have been identified, neither of which show...

20060014935 - Fas ligand derived polypeptides: This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide,...

20060014936 - Hybrid bacillus thuringiensis cry1a/cry1f dna and plants and host cells transformed with same: Disclosed are novel synthetically-modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Methods of making and using these genes and proteins are disclosed as well as methods for the recombinant expression, and...

20060014937 - Humanized antibody against s-surface antigen of hepatitis b virus: A humanized antibody of the present invention shows similar antigen-binding affinity to a mouse monoclonal antibody and significantly low immunogenecity. Therefore, the humanized antibody of the present invention can be effectively used for treating chronic hepatitis B and preventing HBV infection of a patient received liver transplantation and vertical transmission...

20060009618 - Expression receptors with 7 transmembrane domains in baculovirus-insect cell system: The invention concerns the expression in a baculovirus-insect cell system of receptors with seven transmembrane domains, in particular receptors coupled to proteins (;, in particular olfactory receptors, under the transcriptional control of a promoter derived from the polyhedrin promoter by deletion of all or part of the region of said...

20060009620 - Protein structures and protein fibres: This invention relates to protein fibre formation and in particular to methods of producing protein fibres to form a protein structure comprising a plurality of first polypeptide units arranged in a first polypeptide strand and a plurality of second polypeptide units arranged in a second polypeptide strand, the strands preferably...

20060009619 - Ricin vaccine and methods of making and using thereof: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous...

20060009621 - Antibodies that specifically bind pms2: Antibodies against PMS2 and PMS2-134 and cells that produce the anti-PMS2 and anti-PMS2-134 antibodies are provided. The antibodies of the invention may be used in methods for detecting a PMS2 protein, including a truncated PMS2, and in methods for detecting an abnormal condition in a patient....

20060009623 - C-terminal attachment of ligands to proteins for immobilization onto a support: The present invention provides methods of immobilizing proteins onto a support, using a cellular expression system or a cell-free expression system, to attach a ligand to the C-terminus of the protein, by an intein-mediated or a puromycin-mediated approach. A method for improving the efficiency of intein-mediated ligand attachment is also...

20060009622 - Conjugates of therapeutic or cytotoxic agents and biologically active peptides: The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof....

20060009624 - Stable cyanine dye phosphoramidites: In this formula, each dotted line represents carbon atoms necessary to form a fused substituted or unsubstituted aromatic ring; m is an integer from 1 to 18; Y and Z are independently selected from the group consisting of S, O, N, CH2 and C(CH3)2; R1 is an alkyl; (PAM) is...

20060009625 - Method for purifying a protein of the cystine-knot superfamily: The present invention relates to a two-step method for isolating proteins from the cystine-knot superfamily based on dye ligand affinity chromatography and reversed-phase chromatography. Advantageously, the method can be performed in a relatively short period of time, involves inexpensive reagents, and requires little sample preparation before and during the purification...

20060004184 - Method and device for detecting feline immunodeficiency virus: A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected...

20060004185 - Peptide antibiotics and peptide intermediates for their prepartion: Novel protected cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics. Intermediates are readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; but also are useful and potent against gram-positive bacteria....

20060004187 - Bk beta subunits of slo family potassium channels: The invention provides isolated nucleic acid and amino acid sequences of BK beta 2, BK beta 3, and BK beta 4, antibodies to the BK beta subunits, methods of detecting the BK beta subunits, methods of screening for modulators of Slo potassium channels comprising BK beta subunits, and kits for...

20060004186 - P. ariasi polypeptides, p. perniciosus polypeptides and methods of use: Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments,...

20060004188 - Intermediates and the synthesis of modified carbocyanine dyes and their conjugates: Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein...

20060004189 - Compositions for treating wounds and processes for their preparation: The present invention provides a process for obtaining growth factors by treating a growth factor starting material to release growth factors from the growth factor starting material and recovering growth factors from the treated growth factor starting material. The growth factor obtained can be used in compositions to treat humans....